각막 내피 디스트로피 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 8.1%로 성장할 전망이며, 2,528억 8,000만 달러로 성장이 예측됩니다. 이 예측 기간 동안의 성장은 신흥국에서 각막 실명 유병률 증가, 아이케어에 대한 의식 고조, 각막이식 수요 확대, 헬스케어 인프라 개선, 만성질환 이환율 증가 등에 기인할 것으로 보입니다. 이 기간에 예상되는 주요 동향으로는 재생요법 발전, 의료기술 혁신, 진단 기술 개선, 안과용 레이저 기술 진보, 고도의 안과 솔루션 개발 등이 있습니다.
각막 이식에 대한 수요 증가는 각막 내피 디스트로피 시장의 성장을 가속할 것으로 예측됩니다. 각막이식은 손상 또는 질병의 각막을 건강한 기증자 각막과 교환함으로써 시력을 회복시키고 눈 건강을 증진시키는 외과 수술입니다. 이러한 수요의 증가는 각막 질환 유병률 증가, 수술 기술의 진보, 장기 기증률 향상에 기인하고 있습니다. 각막 내피 디스트로피는 각막 이식을 통해 치료되며 손상된 내피를 건강한 기증자 조직과 대체함으로써 각막의 투명성을 회복하고 부종을 경감하며 시력을 개선합니다. 예를 들어 미국에 거점을 둔 이식 협회인 아이뱅크어소시에이션오브아메리카는 2023년 국내 각막 이식술 건수가 2.7% 증가해 2022년 4만 9597건에서 2023년 5만 925건으로 증가했다고 보고했습니다. 그 결과 각막 이식 수요 증가가 각막 내피 디스트로피 시장의 성장을 촉진하고 있습니다.
각막 내피 디스트로피 시장의 주요 기업은 언멧 메디컬 요구를 충족시키기 위해 동종 세포 요법과 같은 혁신적인 치료법 개발에 주력하고 있습니다. 이러한 혁신적이고 저침습적인 치료법은 환자의 예후를 개선하는 것을 목적으로 하고 있습니다. 동종 세포 요법은 레시피엔트를 치료하기 위해 유전적으로 다른 동종의 기증자 세포를 사용하는 것을 포함합니다. 예를 들면, 2024년 9월, 미국에 거점을 둔 임상 단계의 바이오 테크놀로지 기업인 Aurion Biotech Inc.는 각막 내피 질환인 수포성 각막증의 치료제로서 Vyznova(네르테펜드셀)를 일본에서 발표했습니다. Vyznova는 각막 내피 세포에 손상을 주어 시력 장애를 일으키는 수포성 각막증의 치료를 목적으로 한 세포 치료제입니다. 각막 내피 질환에 대한 세포 치료로는 최초로 승인되었으며, 일본에서도 승인된 바 있습니다. Vyznova는 연구실에서 배양된 각막 내피 세포를 이용하기 때문에 1명의 기증자로부터 최대 1,000회분 투여가 가능합니다. 이 혁신적인 치료법은 각막 이식을 대체할 수 있는 침습이 적은 치료법으로 기증자 각막의 부족에 대처하고 각막 질환 환자의 시력 회복을 위한 새로운 해결책을 제공하는 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 각막 내피 디스트로피 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
- 최종 이용 산업의 분석
- 세계의 각막 내피 디스트로피 시장 : 성장률 분석
- 세계의 각막 내피 디스트로피 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 각막 내피 디스트로피 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 각막 내피 디스트로피 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 각막 내피 디스트로피 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 광선요법 각막절제술
- 양막 이식
- 정면 간질 천자
- 결막 플랩
- 세계의 각막 내피 디스트로피 시장 : 질병 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 선천성 유전성 내피 이영양증 1형
- 선천성 유전성 내피 이영양증 2형
- 후부 다형성 각막 이영양증
- 훅스 각막 내피 디스트로피
- 세계의 각막 내피 디스트로피 시장 : 진단별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 각막 검사 및 등급
- 각막 단층 촬영
- 각막 두께 측정
- 각막 세포 수
- 세계의 각막 내피 디스트로피 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 클리닉
- 기타 최종 사용자
- 세계의 각막 내피 디스트로피 시장 : 광선 요법 각막 절제술 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 엑시머 레이저 요법
- 각막 재형성
- 세계의 각막 내피 디스트로피 시장 : 양막 이식 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 신선한 양막 이식
- 동결보존 양막 이식
- 세계의 각막 내피 디스트로피 시장 : 정면 간질 천자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 수동 테크닉
- 레이저 지원 기술
- 세계의 각막 내피 디스트로피 시장 : 결막 플랩 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 부분피판법
- 풀 플랩 테크닉
제7장 지역별 및 국가별 분석
- 세계의 각막 내피 디스트로피 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 각막 내피 디스트로피 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 각막 내피 디스트로피 시장 : 경쟁 구도
- 각막 내피 디스트로피 시장 : 기업 프로파일
- F. Hoffmann-La Roche AG 개요, 제품 및 서비스, 전략 및 재무 분석
- Abbvie(Allergan plc)개요, 제품 및 서비스, 전략 및 재무 분석
- Teva Pharmaceutical Industries Ltd 개요, 제품 및 서비스, 전략 및 재무 분석
- Fujifilm Holdings Corporation 개요, 제품 및 서비스, 전략 및 재무 분석
- Alcon Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Bausch Health Lomb
- Santen Pharmaceutical Co., Ltd.
- AGC Biologics Inc
- Lumenis Ltd
- Aurion Biotech Inc
- Carl Zeiss Meditec AG
- Keeler Limited
- Kowa Company Ltd.
- ProQR Therapeutics NV
- Cellusion Inc.
- OptoTech GmbH
- ActualEyes Inc.
- Arctic Vision Inc.
- Aurion Biotech LLC
- Emmecell SRL
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 각막 내피 디스트로피 시장(2029년) : 새로운 기회를 제공하는 국가
- 각막 내피 디스트로피 시장(2029년) : 새로운 기회를 제공하는 부문
- 각막 내피 디스트로피 시장(2029년) : 성장 전략
제36장 부록
AJY
Corneal endothelial dystrophy is a genetic eye disorder affecting the cornea's endothelium (inner cell layer), resulting in a gradual loss of corneal clarity. This condition is marked by the degeneration of endothelial cells, which are essential for maintaining the cornea's fluid balance.
The primary treatment options for corneal endothelial dystrophy include phototherapeutic keratectomy (PTK), amniotic membrane transplants, anterior stromal puncture, and conjunctival flaps. PTK is a laser procedure used to remove superficial corneal layers, addressing surface irregularities and scarring. These treatments are applied to various disease types, such as congenital hereditary endothelial dystrophy 1 and 2, posterior polymorphous corneal dystrophy, and Fuchs' endothelial corneal dystrophy. Diagnosis methods include corneal examination and grading, corneal tomography, corneal pachymetry, and corneal cell count. These treatments are utilized by different end-users, including hospitals, clinics, and other healthcare facilities.
The corneal endothelial dystrophy market research report is one of a series of new reports from The Business Research Company that provides corneal endothelial dystrophy market statistics, including the corneal endothelial dystrophy industry global market size, regional shares, competitors with the corneal endothelial dystrophy market share, detailed corneal endothelial dystrophy market segments, market trends, and opportunities, and any further data you may need to thrive in the corneal endothelial dystrophy industry. This corneal endothelial dystrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The corneal endothelial dystrophy market size has grown strongly in recent years. It will grow from $170.96 billion in 2024 to $185.38 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to increasing healthcare expenditures, a rising prevalence of endothelial corneal dystrophy, a growing aging population, a higher incidence of eye diseases, and a surge in corneal disorders.
The corneal endothelial dystrophy market size is expected to see strong growth in the next few years. It will grow to $252.88 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The projected growth in the forecast period can be attributed to the increasing prevalence of corneal blindness in emerging economies, rising awareness about eye care, growing demand for corneal transplantation, improvements in healthcare infrastructure, and a higher incidence of chronic disorders. Key trends expected during this period include advancements in regenerative therapies, innovations in medical technology, improvements in diagnostic techniques, technological progress in ophthalmic lasers, and the development of advanced ophthalmic solutions.
The increasing demand for corneal transplantation is anticipated to drive the growth of the corneal endothelial dystrophy market. Corneal transplantation is a surgical procedure that replaces a damaged or diseased cornea with a healthy donor cornea to restore vision and enhance eye health. This rising demand is attributed to the growing prevalence of corneal diseases, advancements in surgical techniques, and improved organ donation rates. Corneal endothelial dystrophy is treated through corneal transplantation, which replaces the damaged endothelium with healthy donor tissue, restoring corneal clarity, reducing edema, and improving vision. For example, in 2023, the Eye Bank Association of America, a US-based transplant association, reported a 2.7% increase in domestic keratoplasty procedures, rising from 49,597 in 2022 to 50,925 in 2023. As a result, the increasing demand for corneal transplantation is propelling the growth of the corneal endothelial dystrophy market.
Leading companies in the corneal endothelial dystrophy market are focusing on the development of innovative treatments, such as allogeneic cell therapy, to address unmet medical needs. These innovative, minimally invasive treatment options aim to improve patient outcomes. Allogeneic cell therapy involves using cells from a genetically distinct donor of the same species to treat a recipient. For instance, in September 2024, Aurion Biotech Inc., a US-based clinical-stage biotech company, introduced Vyznova (neltependocel) in Japan for the treatment of bullous keratopathy, a corneal endothelial disease. Vyznova is a cell therapy designed to treat bullous keratopathy, which damages corneal endothelial cells and causes vision impairment. It is the first approved cell therapy for corneal endothelial disease and has received approval in Japan. Vyznova utilizes corneal endothelial cells cultured in a lab, enabling the production of up to 1,000 doses from a single donor. This innovative therapy provides a less invasive alternative to corneal transplants, helping to address the shortage of donor corneas and offering a new solution for restoring vision in patients with corneal diseases.
In February 2024, Eversight, a US-based nonprofit eye bank, collaborated with Emmecell to advance minimally invasive cell therapies for corneal endothelial diseases. This partnership aims to develop treatments for conditions such as corneal edema caused by endothelial cell dysfunction and expand access to innovative therapies worldwide. Emmecell, a US-based biotechnology company, is working on a non-surgical cell therapy to address corneal edema, a condition frequently resulting from corneal endothelial dysfunction.
Major players in the corneal endothelial dystrophy market are F. Hoffmann-La Roche AG, Abbvie (Allergan plc), Teva Pharmaceutical Industries Ltd, Fujifilm Holdings Corporation, Alcon Inc., Bausch Health+Lomb, Santen Pharmaceutical Co., Ltd., AGC Biologics Inc, Lumenis Ltd, Aurion Biotech Inc, Carl Zeiss Meditec AG, Keeler Limited, Kowa Company Ltd., ProQR Therapeutics N.V., Cellusion Inc., OptoTech GmbH, ActualEyes Inc., Arctic Vision Inc., Aurion Biotech LLC, Emmecell S.R.L.
North America was the largest region in the corneal endothelial dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in corneal endothelial dystrophy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the corneal endothelial dystrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The corneal endothelial dystrophy market consists of revenues earned by entities by providing services such as endothelial keratoplasty, specialized contact lenses, and penetrating keratoplasty. The market value includes the value of related goods sold by the service provider or included within the service offering. The corneal endothelial dystrophy market also includes sales of medications, corneal implants, surgical instruments, diagnostic devices, cell therapy products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Corneal Endothelial Dystrophy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on corneal endothelial dystrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for corneal endothelial dystrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The corneal endothelial dystrophy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment: Phototherapeutic Keratectomy; Amniotic Membrane Transplants; Anterior Stromal Puncture; Conjunctival Flaps
- 2) By Disease Type: Congenital Hereditary Endothelial Dystrophy 1; Congenital Hereditary Endothelial Dystrophy 2; Posterior Polymorphous Corneal Dystrophy; Fuchs Endothelial Corneal Dystrophy
- 3) By Diagnosis: Cornea Examination And Grading; Corneal Tomography; Corneal Pachymetry; Corneal Cell Count
- 4) By End-User: Hospitals; Clinics; Other End Users
- Subsegments:
- 1) By Phototherapeutic Keratectomy: Excimer Laser Therapy; Corneal Reshaping
- 2) By Amniotic Membrane Transplants: Fresh Amniotic Membrane Transplant; Cryopreserved Amniotic Membrane Transplant
- 3) By Anterior Stromal Puncture: Manual Technique; Laser-Assisted Technique
- 4) By Conjunctival Flaps: Partial Flap Technique; Full Flap Technique
- Companies Mentioned: F. Hoffmann-La Roche AG; Abbvie (Allergan plc); Teva Pharmaceutical Industries Ltd; Fujifilm Holdings Corporation; Alcon Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Corneal Endothelial Dystrophy Market Characteristics
3. Corneal Endothelial Dystrophy Market Trends And Strategies
4. Corneal Endothelial Dystrophy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Corneal Endothelial Dystrophy Growth Analysis And Strategic Analysis Framework
- 5.1. Global Corneal Endothelial Dystrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Corneal Endothelial Dystrophy Market Growth Rate Analysis
- 5.4. Global Corneal Endothelial Dystrophy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Corneal Endothelial Dystrophy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Corneal Endothelial Dystrophy Total Addressable Market (TAM)
6. Corneal Endothelial Dystrophy Market Segmentation
- 6.1. Global Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Phototherapeutic Keratectomy
- Amniotic Membrane Transplants
- Anterior Stromal Puncture
- Conjunctival Flaps
- 6.2. Global Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Congenital Hereditary Endothelial Dystrophy 1
- Congenital Hereditary Endothelial Dystrophy 2
- Posterior Polymorphous Corneal Dystrophy
- Fuchs Endothelial Corneal Dystrophy
- 6.3. Global Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Cornea Examination And Grading
- Corneal Tomography
- Corneal Pachymetry
- Corneal Cell Count
- 6.4. Global Corneal Endothelial Dystrophy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Other End Users
- 6.5. Global Corneal Endothelial Dystrophy Market, Sub-Segmentation Of Phototherapeutic Keratectomy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Excimer Laser Therapy
- Corneal Reshaping
- 6.6. Global Corneal Endothelial Dystrophy Market, Sub-Segmentation Of Amniotic Membrane Transplants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Fresh Amniotic Membrane Transplant
- Cryopreserved Amniotic Membrane Transplant
- 6.7. Global Corneal Endothelial Dystrophy Market, Sub-Segmentation Of Anterior Stromal Puncture, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Manual Technique
- Laser-Assisted Technique
- 6.8. Global Corneal Endothelial Dystrophy Market, Sub-Segmentation Of Conjunctival Flaps, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Partial Flap Technique
- Full Flap Technique
7. Corneal Endothelial Dystrophy Market Regional And Country Analysis
- 7.1. Global Corneal Endothelial Dystrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Corneal Endothelial Dystrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Corneal Endothelial Dystrophy Market
- 8.1. Asia-Pacific Corneal Endothelial Dystrophy Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Corneal Endothelial Dystrophy Market
- 9.1. China Corneal Endothelial Dystrophy Market Overview
- 9.2. China Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Corneal Endothelial Dystrophy Market
- 10.1. India Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Corneal Endothelial Dystrophy Market
- 11.1. Japan Corneal Endothelial Dystrophy Market Overview
- 11.2. Japan Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Corneal Endothelial Dystrophy Market
- 12.1. Australia Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Corneal Endothelial Dystrophy Market
- 13.1. Indonesia Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Corneal Endothelial Dystrophy Market
- 14.1. South Korea Corneal Endothelial Dystrophy Market Overview
- 14.2. South Korea Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Corneal Endothelial Dystrophy Market
- 15.1. Western Europe Corneal Endothelial Dystrophy Market Overview
- 15.2. Western Europe Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Corneal Endothelial Dystrophy Market
- 16.1. UK Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Corneal Endothelial Dystrophy Market
- 17.1. Germany Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Corneal Endothelial Dystrophy Market
- 18.1. France Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Corneal Endothelial Dystrophy Market
- 19.1. Italy Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Corneal Endothelial Dystrophy Market
- 20.1. Spain Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Corneal Endothelial Dystrophy Market
- 21.1. Eastern Europe Corneal Endothelial Dystrophy Market Overview
- 21.2. Eastern Europe Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Corneal Endothelial Dystrophy Market
- 22.1. Russia Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Corneal Endothelial Dystrophy Market
- 23.1. North America Corneal Endothelial Dystrophy Market Overview
- 23.2. North America Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Corneal Endothelial Dystrophy Market
- 24.1. USA Corneal Endothelial Dystrophy Market Overview
- 24.2. USA Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Corneal Endothelial Dystrophy Market
- 25.1. Canada Corneal Endothelial Dystrophy Market Overview
- 25.2. Canada Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Corneal Endothelial Dystrophy Market
- 26.1. South America Corneal Endothelial Dystrophy Market Overview
- 26.2. South America Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Corneal Endothelial Dystrophy Market
- 27.1. Brazil Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Corneal Endothelial Dystrophy Market
- 28.1. Middle East Corneal Endothelial Dystrophy Market Overview
- 28.2. Middle East Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Corneal Endothelial Dystrophy Market
- 29.1. Africa Corneal Endothelial Dystrophy Market Overview
- 29.2. Africa Corneal Endothelial Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Corneal Endothelial Dystrophy Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Corneal Endothelial Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Corneal Endothelial Dystrophy Market Competitive Landscape And Company Profiles
- 30.1. Corneal Endothelial Dystrophy Market Competitive Landscape
- 30.2. Corneal Endothelial Dystrophy Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Abbvie (Allergan plc) Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Teva Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Alcon Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Corneal Endothelial Dystrophy Market Other Major And Innovative Companies
- 31.1. Bausch Health+Lomb
- 31.2. Santen Pharmaceutical Co., Ltd.
- 31.3. AGC Biologics Inc
- 31.4. Lumenis Ltd
- 31.5. Aurion Biotech Inc
- 31.6. Carl Zeiss Meditec AG
- 31.7. Keeler Limited
- 31.8. Kowa Company Ltd.
- 31.9. ProQR Therapeutics N.V.
- 31.10. Cellusion Inc.
- 31.11. OptoTech GmbH
- 31.12. ActualEyes Inc.
- 31.13. Arctic Vision Inc.
- 31.14. Aurion Biotech LLC
- 31.15. Emmecell S.R.L
32. Global Corneal Endothelial Dystrophy Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Corneal Endothelial Dystrophy Market
34. Recent Developments In The Corneal Endothelial Dystrophy Market
35. Corneal Endothelial Dystrophy Market High Potential Countries, Segments and Strategies
- 35.1 Corneal Endothelial Dystrophy Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Corneal Endothelial Dystrophy Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Corneal Endothelial Dystrophy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
